

Special Issue

Recent Advances in the Improvement of the Therapeutic Index of DNA Repair Inhibitors in Standalone or in Combination Therapy

Message from the Guest Editor

50 years ago, Goodman and Gilman, in *Pharmacologic Basis of Therapeutics* (1970), described the relationship between desired and undesired effects of therapy as the therapeutic index (TI), which is defined as the margin of safety that exists between the dose that produces the desired effect and the dose that produces unwanted and possibly dangerous side-effects. Improving the relationship between desired and undesired effects of therapy is a major goal of cancer therapy. A major challenge in the development of cancer therapeutics is the identification of biological targets and pathways, and the subsequent design of molecules to fight cancer cells. All cancers display defects in DNA repair, and the ability of cancer cells to repair therapeutically induced DNA damage impacts therapeutic efficacy.

This Special Issue of *Cancers* therefore encompasses new research articles and timely reviews on all aspects of the development of DNA repair inhibitors, with a special focus on the improvement of the therapeutic index

Guest Editor

Dr. Pierre-Marie Girard

Institut Curie, Centre de Recherche, Université Paris-Saclay, Bâtiment 112, Unité de recherche U1021-UMR3347, Rue Henry Becquerel, CS 90030, 91401 ORSAY cedex, France

Deadline for manuscript submissions

closed (30 April 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/50067

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)